p73: From the p53 shadow to a major pharmacological target in anticancer therapy

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Ramos, H (Author) Other; Raimundo, L (Author) Other; Lucilia Saraiva (Author) FFUP

Journal

Title: Pharmacological Research

Vol. 162

ISSN: 1043-6618

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 4 Citations

Other information

Authenticus ID: P-00T-0Y9

DOI: 10.1016/j.phrs.2020.105245

Abstract (EN): p73, along with p53 and p63, belongs to the p53 family of transcription factors. Besides the p53-like tumor suppressive activities, p73 has unique roles, namely in neuronal development and differentiation. In addition, the TP73 gene is rarely mutated in tumors. This makes p73 a highly appealing therapeutic target, particularly towards cancers with a null or disrupted p53 pathway. Distinct isoforms are transcribed from the TP73 locus either with (TAp73) and without (Delta Np73) the N-terminal transactivation domain. Conversely to TA tumor suppressors, Delta N proteins exhibit oncogenic properties by inhibiting p53 and TA protein functions. As such, p73 isoforms compose a puzzled and challenging regulatory pathway. This state-of-the-art review affords an update overview on p73 structure, biological functions and pharmacological regulation. Importantly, it addresses the relevance of p73 isoforms in carcinogenesis, highlighting their potential as drug targets in anticancer therapy. A critical discussion of major pharmacological approaches to promote p73 tumor suppressive activities, with relevant survival outcomes for cancer patients, is also provided.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 13